Note from June 29, 2020
Although we do not yet know how long the social distancing related to the Covid-19 pandemic will last, and regardless of the changes that had to be made in the evaluation of the June 2020 session in relation to what is provided for in this learning unit description, new learnig unit evaluation methods may still be adopted by the teachers; details of these methods have been - or will be - communicated to the students by the teachers, as soon as possible.
Although we do not yet know how long the social distancing related to the Covid-19 pandemic will last, and regardless of the changes that had to be made in the evaluation of the June 2020 session in relation to what is provided for in this learning unit description, new learnig unit evaluation methods may still be adopted by the teachers; details of these methods have been - or will be - communicated to the students by the teachers, as soon as possible.
3 credits
30.0 h + 15.0 h
Q2
Teacher(s)
Dessy Chantal; Duhoux François (compensates Hermans Emmanuel); Dujardin Nathalie; Spinewine Anne (coordinator); Wertz Aline (compensates Hermans Emmanuel);
Language
French
Prerequisites
Physiopathology, general pharmacology, pharmacodynamics and pharmacokinetics, pharmacology and pharmacotherapy
Main themes
Upon completion of this course, the pharmacist should be able to:
- explain the pharmacokinetic and pharmacodynamic factors that need to be taken into account in these specific populations, when prescribing medicines
- explain the indications and contra-indications specific to each population
- understand and to manage drug interactions in these populations
- evaluate the adequacy of drug dosages
- provide appropriate counselling to patients and carers relative to their drug regimen
- discuss with other health care professionals the rational use of medicines in these specific populations
- summarise and critically appraise a published paper relative to a clinical trial relative to pharmacotherapy in the abovementioned populations.
- explain the pharmacokinetic and pharmacodynamic factors that need to be taken into account in these specific populations, when prescribing medicines
- explain the indications and contra-indications specific to each population
- understand and to manage drug interactions in these populations
- evaluate the adequacy of drug dosages
- provide appropriate counselling to patients and carers relative to their drug regimen
- discuss with other health care professionals the rational use of medicines in these specific populations
- summarise and critically appraise a published paper relative to a clinical trial relative to pharmacotherapy in the abovementioned populations.
Aims
At the end of this learning unit, the student is able to : | |
| 1 |
To acquire knowledge and skills in the pharmaceutical care of specific populations, including infants and children, elderly people, pregnant women, and drug abusers. |
The contribution of this Teaching Unit to the development and command of the skills and learning outcomes of the programme(s) can be accessed at the end of this sheet, in the section entitled “Programmes/courses offering this Teaching Unit”.
Content
- interactive teaching in relation to the objectives stated above, taking into account recent evidence and clinical guidelines on the rational use of medicines in these populations
- learning based on exercices: pharmaceutical care plans, critical appraisal of therapeutic failures.
- learning based on exercices: pharmaceutical care plans, critical appraisal of therapeutic failures.
Evaluation methods
1° written examination with questions to evaluate knowledge and skills (ie theory and practice-based questions)
2° oral presentation of a journal club relative to a paper relative to a specific aspect of pharmacotherapy in a specific population addressed in the present course.
2° oral presentation of a journal club relative to a paper relative to a specific aspect of pharmacotherapy in a specific population addressed in the present course.
Faculty or entity
FARM
